Latest news about Gujarat Terce Laboratories
Gujarat Terce Laboratories
36.48
+1.83(+5.28%)
Company Performance:
View Company Insights1D+5.28%
1M+12.25%
6M-20.63%
1Y-38.68%
5Y+266.63%
More news about Gujarat Terce Laboratories
08Nov 25
Gujarat Terce Laboratories Reports Record EBITDA Despite Revenue Dip in Q2 FY26
Gujarat Terce Laboratories Limited achieved its highest-ever EBITDA of Rs 194.46 lacs in Q2 FY26, up 11.62% year-over-year, despite a 2.82% revenue decline to Rs 1,292.63 lacs. The EBITDA margin expanded to 15.04% from 13.10%. Net profit decreased by 5.30% to Rs 140.36 lacs. The company attributes the revenue reduction to planned scale-down of low-margin factory B2B sales and rationalization of non-profitable operations. Operating without external funding for three quarters, the pharmaceutical firm has a presence in 13 states with 8 leading brands across 134 products.
11Aug 25
Gujarat Terce Laboratories Reports Q1 Loss, Reshuffles Board Committees
Gujarat Terce Laboratories Limited reported a net loss of Rs 4.35 lakhs for Q1, an improvement from Rs 7.76 lakhs loss in the previous year. Revenue decreased to Rs 1,085.36 lakhs from Rs 1,188.88 lakhs. The company reconstituted its Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees. Statutory auditors provided an unmodified opinion on the quarterly results.
26Jul 25
Gujarat Terce Laboratories Reports Net Loss Despite Revenue Growth, Settles Tax Disputes
Gujarat Terce Laboratories Limited reported a 3.93% increase in total revenue to ₹50.20 crore, with sales rising 4.58% to ₹50.20 crore. EBITDA surged 143.12% to ₹3.89 crore, improving the EBITDA margin from 3.31% to 7.75%. However, the company faced a net loss of ₹0.98 crore due to a one-time tax settlement provision of ₹3.42 crore. The company reduced its debt-to-equity ratio from 0.54 to 0.15 and achieved zero borrowing in Q4. Operational improvements included better inventory and receivables management.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
